Uri Levental, Yuly Bersudsky, Tzvi Dwalatzky, Vladimir Lerner, Sophie Medina, Joseph Levine
{"title":"长期高剂量肌酸增强治疗难治性阴性症状精神分裂症患者的试点开放研究","authors":"Uri Levental, Yuly Bersudsky, Tzvi Dwalatzky, Vladimir Lerner, Sophie Medina, Joseph Levine","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The effects of creatine on brain metabolism and the potential cognitive enhancing properties of this compound raise the possibility of developing a new augmentation therapeutic strategy in schizophrenia especially in patients demonstrating negative and cognitive symptomatology.</p><p><strong>Methods: </strong>Seven inpatients with chronic schizophrenia presenting with treatment resistant negative symptoms were enrolled into exploratory treatment study with creatine monohydrate augmentation at a daily high-dose of 10 grams, administered for 6 months. Several clinical rating scales and a computerized cognitive assessment battery were applied.</p><p><strong>Results: </strong>Creatine treatment mildly improved the schizophrenia symptomatology but there were no significant changes in cognitive functions. Several ward behaviors were also improved. Tardive parkinsonism improved numerically by above 40% in 4 out of 6 patients.</p><p><strong>Conclusion: </strong>This small, open design study of high dose creatine add-on for 6 months in chronic inpatients with schizophrenia demonstrated only mild positive effects on the patients' symptomatology and behavior and might have beneficial effect on tardive parkinsonism.</p>","PeriodicalId":49288,"journal":{"name":"Israel Journal of Psychiatry and Related Sciences","volume":"52 1","pages":"6-10"},"PeriodicalIF":0.5000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A pilot open study of long term high dose creatine augmentation in patients with treatment resistant negative symptoms schizophrenia.\",\"authors\":\"Uri Levental, Yuly Bersudsky, Tzvi Dwalatzky, Vladimir Lerner, Sophie Medina, Joseph Levine\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The effects of creatine on brain metabolism and the potential cognitive enhancing properties of this compound raise the possibility of developing a new augmentation therapeutic strategy in schizophrenia especially in patients demonstrating negative and cognitive symptomatology.</p><p><strong>Methods: </strong>Seven inpatients with chronic schizophrenia presenting with treatment resistant negative symptoms were enrolled into exploratory treatment study with creatine monohydrate augmentation at a daily high-dose of 10 grams, administered for 6 months. Several clinical rating scales and a computerized cognitive assessment battery were applied.</p><p><strong>Results: </strong>Creatine treatment mildly improved the schizophrenia symptomatology but there were no significant changes in cognitive functions. Several ward behaviors were also improved. Tardive parkinsonism improved numerically by above 40% in 4 out of 6 patients.</p><p><strong>Conclusion: </strong>This small, open design study of high dose creatine add-on for 6 months in chronic inpatients with schizophrenia demonstrated only mild positive effects on the patients' symptomatology and behavior and might have beneficial effect on tardive parkinsonism.</p>\",\"PeriodicalId\":49288,\"journal\":{\"name\":\"Israel Journal of Psychiatry and Related Sciences\",\"volume\":\"52 1\",\"pages\":\"6-10\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Israel Journal of Psychiatry and Related Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Israel Journal of Psychiatry and Related Sciences","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
A pilot open study of long term high dose creatine augmentation in patients with treatment resistant negative symptoms schizophrenia.
Background: The effects of creatine on brain metabolism and the potential cognitive enhancing properties of this compound raise the possibility of developing a new augmentation therapeutic strategy in schizophrenia especially in patients demonstrating negative and cognitive symptomatology.
Methods: Seven inpatients with chronic schizophrenia presenting with treatment resistant negative symptoms were enrolled into exploratory treatment study with creatine monohydrate augmentation at a daily high-dose of 10 grams, administered for 6 months. Several clinical rating scales and a computerized cognitive assessment battery were applied.
Results: Creatine treatment mildly improved the schizophrenia symptomatology but there were no significant changes in cognitive functions. Several ward behaviors were also improved. Tardive parkinsonism improved numerically by above 40% in 4 out of 6 patients.
Conclusion: This small, open design study of high dose creatine add-on for 6 months in chronic inpatients with schizophrenia demonstrated only mild positive effects on the patients' symptomatology and behavior and might have beneficial effect on tardive parkinsonism.
期刊介绍：
THE ISRAEL JOURNAL OF PSYCHIATRY publishes original articles dealing with the all bio-psycho-social aspects of psychiatry. While traditionally the journal has published manuscripts relating to mobility, relocation, acculturation, ethnicity, stress situations in war and peace, victimology and mental health in developing countries, papers addressing all aspects of the psychiatry including neuroscience, biological psychiatry, psychopharmacology, psychotherapy and ethics are welcome. The Editor also welcomes pertinent book reviews and correspondence. Preference is given to research reports of no more than 5,000 words not including abstract, text, references, tables and figures. There should be no more than 40 references and 4 tables or figures. Brief reports (1,500 words, 5 references) are considered if they have heuristic value. Books to be considered for review should be sent to the editorial office. Selected book reviews are invited by the editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
